Systematic review with network meta‐analysis: comparative assessment of tofacitinib and biological therapies for moderate‐to‐severe ulcerative colitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|4|454-465

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.4, 2018-02, pp. : 454-465

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 539-540

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative efficacy of biological treatments for moderate‐to‐severe psoriasis: a network meta‐analysis adjusting for cross‐trial differences in reference arm response

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 2, 2015-02 ,pp. : 504-512

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 540-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review and meta‐analysis of ustekinumab for moderate to severe psoriasis: comment

By  

CLINICAL & EXPERIMENTAL DERMATOLOGY, Vol. 40, Iss. 7, 2015-10 ,pp. : 810-811

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review and meta‐analysis of ustekinumab for moderate to severe psoriasis: comment

By  

CLINICAL & EXPERIMENTAL DERMATOLOGY, Vol. 307-6938, Iss. 7, 2015-10 ,pp. : 810-811

John Wiley & Sons Inc

Access to resources Recommend Favorite